These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32387308)

  • 1. Nanoemulsion as a feasible and biocompatible carrier for ocular delivery of travoprost: Improved pharmacokinetic/pharmacodynamic properties.
    Ismail A; Nasr M; Sammour O
    Int J Pharm; 2020 Jun; 583():119402. PubMed ID: 32387308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Betaxolol hydrochloride loaded chitosan nanoparticles for ocular delivery and their anti-glaucoma efficacy.
    Jain K; Kumar RS; Sood S; Dhyanandhan G
    Curr Drug Deliv; 2013 Oct; 10(5):493-9. PubMed ID: 23410069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spanlastics nanovesicular ocular insert as a novel ocular delivery of travoprost: optimization using Box-Behnken design and
    Shukr MH; Ismail S; El-Hossary GG; El-Shazly AH
    J Liposome Res; 2022 Dec; 32(4):354-364. PubMed ID: 35037560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine.
    Kim SN; Ko SA; Park CG; Lee SH; Huh BK; Park YH; Kim YK; Ha A; Park KH; Choy YB
    Mol Pharm; 2018 Aug; 15(8):3143-3152. PubMed ID: 30020792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized crossover trial comparing effectiveness and tolerability of generic and brand-name travoprost.
    Ta Kim D; Daigle P; Carbonneau M
    Can J Ophthalmol; 2019 Apr; 54(2):223-228. PubMed ID: 30975346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of topical travoprost 0.004% on intraocular pressure and corneal biomechanical properties in an animal model.
    Lazcano-Gomez G; Ancona-Lezama D; Gil-Carrasco F; Jimenez-Roman J
    Digit J Ophthalmol; 2016; 22(1):1-5. PubMed ID: 27330476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension.
    Hughes BA; Bacharach J; Craven ER; Kaback MB; Mallick S; Landry TA; Bergamini MV
    J Glaucoma; 2005 Oct; 14(5):392-9. PubMed ID: 16148589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of hyaluronan as a drug carrier to enhance the bioavailability of extended release ophthalmic formulations. Hyaluronan-timolol ionic complexes as a model case.
    Battistini FD; Tártara LI; Boiero C; Guzmán ML; Luciani-Giaccobbe LC; Palma SD; Allemandi DA; Manzo RH; Olivera ME
    Eur J Pharm Sci; 2017 Jul; 105():188-194. PubMed ID: 28506871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs.
    Eisenberg DL; Toris CB; Camras CB
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S105-15. PubMed ID: 12204706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Safety of Travoprost 0.004% Ophthalmic Solution Preserved with Polyquad in Pediatric Patients with Glaucoma.
    Stahl E; Bremond-Gignac D; Landry T; Curtis M; Gedif K; Al Shahwan S; Dixon ER
    J Ocul Pharmacol Ther; 2017 Jun; 33(5):361-365. PubMed ID: 28437175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced bioavailability and antihypertensive activity of nisoldipine loaded nanoemulsion: optimization, cytotoxicity and uptake across Caco-2 cell line, pharmacokinetic and pharmacodynamic studies.
    Mundada VP; Patel MH; Mundada PK; Sawant KK
    Drug Dev Ind Pharm; 2020 Mar; 46(3):376-387. PubMed ID: 32031412
    [No Abstract]   [Full Text] [Related]  

  • 12. Travoprost--a new prostaglandin analogue for the treatment of glaucoma.
    Whitson JT
    Expert Opin Pharmacother; 2002 Jul; 3(7):965-77. PubMed ID: 12083996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study.
    Reardon G; Schwartz GF; Mozaffari E
    Clin Ther; 2003 Apr; 25(4):1172-85. PubMed ID: 12809964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aqueous humor concentrations of bimatoprost free acid, bimatoprost and travoprost free acid in cataract surgical patients administered multiple topical ocular doses of LUMIGAN or TRAVATAN.
    Faulkner R; Sharif NA; Orr S; Sall K; Dubiner H; Whitson JT; Moster M; Craven ER; Curtis M; Pailliotet C; Martens K; Dahlin D
    J Ocul Pharmacol Ther; 2010 Apr; 26(2):147-56. PubMed ID: 20307216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, optimisation and evaluation of in situ gelling nanoemulsion formulations of brinzolamide.
    Bhalerao H; Koteshwara KB; Chandran S
    Drug Deliv Transl Res; 2020 Apr; 10(2):529-547. PubMed ID: 31820300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
    Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost.
    Aihara M; Ikeda Y; Mizoue S; Arakaki Y; Kita N; Kobayashi S;
    J Glaucoma; 2016 Jun; 25(6):e610-4. PubMed ID: 25967526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution.
    Denis P; Andrew R; Wells D; Friren B
    Eur J Ophthalmol; 2006; 16(3):407-15. PubMed ID: 16761242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. iDose TR - a travoprost implant for glaucoma.
    Med Lett Drugs Ther; 2024 Apr; 66(1701):70-71. PubMed ID: 38691647
    [No Abstract]   [Full Text] [Related]  

  • 20. Central corneal thickness during treatment with travoprost 0.004% in glaucoma patients.
    Schlote T; Tzamalis A; Kynigopoulos M
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):459-62. PubMed ID: 19857108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.